{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:07Z","timestamp":1790701747758,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Healthcare A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Persistent post-traumatic headache (PTH) is a common sequela of mild traumatic brain injury (TBI) and retrospective assessments have found a migraine-like phenotype to be very frequent. This has raised a discussion of shared underlying mechanisms and whether persistent PTH is simply trauma-triggered migraine.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A 28-day prospective diary study with daily entries and acquisition of data on headache characteristics, associated symptoms, and acute medication use. A total of 64 patients with persistent PTH were enrolled from April 2019 to August 2019. Outcomes were the proportion of monthly headache days of any intensity that met the criteria for a migraine-like day or TTH-like day, as well as the corresponding figures for monthly headache days of moderate to severe intensity. Headache phenotypes were initially assigned based on diagnostic evaluation by semi-structured interview, whilst final headache phenotypes were assigned by diary review.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After diary review, we found that monthly headache days were exclusively migraine-like in 24 of 64 patients (38%) and exclusively TTH-like days in 8 of 64 patients (13%). Considering only monthly headache days of moderate to severe intensity, the corresponding figures were 35 of 64 patients (55%) for migraine-like days and 8 of 64 patients (13%) for TTH-like days. The following headache phenotypes were assigned based on diary review: chronic migraine-like (<jats:italic>n<\/jats:italic>\u2009=\u200947, 73%), combined episodic migraine-like and chronic TTH-like (<jats:italic>n<\/jats:italic>\u2009=\u20099, 13%), and \u2018pure\u2019 chronic TTH-like (<jats:italic>n<\/jats:italic>\u2009=\u20098, 13%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A migraine-like phenotype is common in patients most adversely affected by persistent PTH, although some patients did have a pure chronic TTH-like phenotype. At minimum, these findings suggest that persistent PTH is \u2013 at least in some \u2013 not \u2018trauma-triggered migraine\u2019.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s10194-020-01202-6","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T22:56:29Z","timestamp":1605826589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study"],"prefix":"10.1186","volume":"21","author":[{"given":"H\u00e5kan","family":"Ashina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrim","family":"Iljazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik W.","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.300.6.711","volume":"300","author":"DE Nampiaparampil","year":"2008","unstructured":"Nampiaparampil DE (2008) Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA 300:711\u2013719","journal-title":"JAMA"},{"key":"1202_CR2","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders (ICHD), 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"1202_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3171\/jns.1988.68.2.0181","volume":"68","author":"DC Haas","year":"1988","unstructured":"Haas DC, Lourie H (1988) Trauma-triggered migraine: an explanation for common neurological attacks after mild head injury. Review of the literature. J Neurosurg 68:181\u2013188","journal-title":"J Neurosurg"},{"key":"1202_CR4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0333102420909865","volume":"40","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM et al (2020) Persistent post-traumatic headache attributed to mild traumatic brain injury: deep phenotyping and treatment patterns. Cephalalgia 40:554\u2013564","journal-title":"Cephalalgia"},{"key":"1202_CR5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/head.12123","volume":"53","author":"B Theeler","year":"2013","unstructured":"Theeler B, Lucas S, Riechers RG II et al (2013) Post-traumatic headaches in civilians and military personnel: a comparative, clinical review. Headache 53:881\u2013900","journal-title":"Headache"},{"key":"1202_CR6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1526-4610.1991.hed3107451.x","volume":"31","author":"HD Weiss","year":"1991","unstructured":"Weiss HD, Stern BJ, Goldberg J (1991) Post-traumatic migraine: chronic migraine precipitated by minor head or neck trauma. Headache 31:451\u2013456","journal-title":"Headache"},{"key":"1202_CR7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11916-015-0520-1","volume":"19","author":"S Lucas","year":"2015","unstructured":"Lucas S (2015) Posttraumatic headache: clinical characterization and management. Curr Pain Headache Rep 19:48","journal-title":"Curr Pain Headache Rep"},{"key":"1202_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s10194-020-01136-z","volume":"21","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM et al (2020) Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain 21:62","journal-title":"J Headache Pain"},{"key":"1202_CR9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s10194-019-1051-7","volume":"20","author":"EL Larsen","year":"2019","unstructured":"Larsen EL, Ashina H, Iljazi A et al (2019) Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. J Headache Pain 20:98","journal-title":"J Headache Pain"},{"key":"1202_CR10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41582-019-0243-8","volume":"15","author":"H Ashina","year":"2019","unstructured":"Ashina H, Porreca F, Anderson T et al (2019) Post-traumatic headache: epidemiology and pathophysiological insights. Nat Rev Neurol 15:607\u2013617","journal-title":"Nat Rev Neurol"},{"key":"1202_CR11","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","journal-title":"JAMA"},{"key":"1202_CR12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/head.13311","volume":"58","author":"S Lucas","year":"2018","unstructured":"Lucas S, Ahn AH (2018) Posttraumatic headache: classification by symptom-based clinical profiles. Headache 58:873\u2013882","journal-title":"Headache"},{"key":"1202_CR13","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1177\/0333102411428954","volume":"31","author":"D Lieba-Samal","year":"2011","unstructured":"Lieba-Samal D, Platzer P, Seidel S et al (2011) Characteristics of acute posttraumatic headache following mild head injury. Cephalalgia 31:1618\u20131626","journal-title":"Cephalalgia"},{"key":"1202_CR14","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1089\/neu.2011.1914","volume":"28","author":"JM Hoffman","year":"2011","unstructured":"Hoffman JM, Lucas S, Dikmen S et al (2011) Natural history of headache after traumatic brain injury. J Neurotrauma 28:1719\u20131725","journal-title":"J Neurotrauma"},{"key":"1202_CR15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/0333102412445224","volume":"32","author":"S Lucas","year":"2012","unstructured":"Lucas S, Hoffman JM, Bell KR et al (2012) Characterization of headache after traumatic brain injury. Cephalalgia 32:600\u2013606","journal-title":"Cephalalgia"},{"key":"1202_CR16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0333102413499645","volume":"34","author":"S Lucas","year":"2014","unstructured":"Lucas S, Hoffman JM, Bell KR et al (2014) A prospective study of prevalence and characterization of headache following mild traumatic brain injury. Cephalalgia 34:93\u2013102","journal-title":"Cephalalgia"},{"key":"1202_CR17","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1089\/neu.2016.4721","volume":"34","author":"A Stacey","year":"2017","unstructured":"Stacey A, Lucas S, Dikmen S et al (2017) Natural history of headache five years after traumatic brain injury. J Neurotrauma 34:1558\u20131564","journal-title":"J Neurotrauma"},{"key":"1202_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-017-0796-0","volume":"18","author":"TJ Schwedt","year":"2017","unstructured":"Schwedt TJ, Chong CD, Peplinski J et al (2017) Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure. J Headache Pain 18:87","journal-title":"J Headache Pain"},{"key":"1202_CR19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/0333102418815650","volume":"39","author":"CD Chong","year":"2019","unstructured":"Chong CD, Peplinski J, Berisha V et al (2019) Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache. Cephalalgia 39:1121\u20131133","journal-title":"Cephalalgia"},{"key":"1202_CR20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0333102419847728","volume":"39","author":"G Dumkrieger","year":"2019","unstructured":"Dumkrieger G, Chong CD, Ross K et al (2019) Static and dynamic functional connectivity differences between migraine and persistent post-traumatic headache: a resting-state magnetic resonance imaging study. Cephalalgia 39:1366\u20131381","journal-title":"Cephalalgia"},{"key":"1202_CR21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3389\/fneur.2019.00615","volume":"10","author":"TJ Schwedt","year":"2019","unstructured":"Schwedt TJ (2019) Structural and functional brain alterations in post-traumatic headache attributed to mild traumatic brain injury: a narrative review. Front Neurol 10:615","journal-title":"Front Neurol"},{"key":"1202_CR22","doi-asserted-by":"publisher","unstructured":"Ashina H, Al-Khazali HM, Iljazi A et al (2020) Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia online ahead of print [20 July 2020]. https:\/\/doi.org\/10.1177\/0333102420941115","DOI":"10.1177\/0333102420941115"},{"key":"1202_CR23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","volume":"16","author":"KD Davis","year":"2020","unstructured":"Davis KD, Aghaeepour N, Ahn AH et al (2020) Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol 16:381\u2013400","journal-title":"Nat Rev Neurol"},{"key":"1202_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183\u2013187","journal-title":"Ann Neurol"},{"key":"1202_CR25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1046\/j.1468-29821995.1505384.x","volume":"15","author":"V Gallai","year":"1995","unstructured":"Gallai V, Sarchielli P, Floridi A et al (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384\u2013390","journal-title":"Cephalalgia"},{"key":"1202_CR26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1202_CR27","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 392:2280\u20132287","journal-title":"Lancet."},{"key":"1202_CR28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122","journal-title":"N Engl J Med"},{"key":"1202_CR29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040","journal-title":"Lancet"},{"key":"1202_CR30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75:1080\u20131088","journal-title":"JAMA Neurol"},{"key":"1202_CR31","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211\u2013e2221","journal-title":"Neurology"},{"key":"1202_CR32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254","journal-title":"Cephalalgia"},{"key":"1202_CR33","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365\u2013e1377","journal-title":"Neurology"},{"key":"1202_CR34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-020-01135-0","volume":"21","author":"S Benemei","year":"2020","unstructured":"Benemei S, Labastida-Ram\u00edrez A, Abramova E et al (2020) Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. J Headache Pain 21:90","journal-title":"J Headache Pain"},{"key":"1202_CR35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s10194-020-01122-5","volume":"21","author":"A Labastida-Ram\u00edrez","year":"2020","unstructured":"Labastida-Ram\u00edrez A, Benemei S, Albanese M et al (2020) Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. J Headache Pain 21:55","journal-title":"J Headache Pain"},{"key":"1202_CR36","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/ijerph17072585","volume":"17","author":"M Capi","year":"2020","unstructured":"Capi M, Pomes LM, Andolina G et al (2020) Persistent post-traumatic headache and migraine: pre-clinical comparisons. Int J Environ Res Public Health 17:2585","journal-title":"Int J Environ Res Public Health"},{"key":"1202_CR37","doi-asserted-by":"crossref","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376.","DOI":"10.1056\/NEJMra1915327"},{"key":"1202_CR38","doi-asserted-by":"publisher","unstructured":"Mitsikostas DD, Moskowitz MA. Making headway \u2014 a role for CGRP in post-traumatic headache. Nat Rev Neurol. 2020.\u00a0https:\/\/doi.org\/10.1038\/s41582-020-00431-2.","DOI":"10.1038\/s41582-020-00431-2"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-020-01202-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T22:56:37Z","timestamp":1605826597000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01202-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01202-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was reviewed by the Regional Health Research Ethics Committee of the Capital Region of Denmark (identifier: H-18050498).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship and\/or publication of this article: Dr. Faisal M. Amin has received personal fees from Eli Lilly, Novartis, and Teva. Dr. Faisal M. Amin is currently a principal investigator of clinical trials funded by Novartis and Teva. Dr. Faisal M. Amin is an associate editor of Headache Medicine. Dr. Messoud Ashina has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. Dr. Messoud Ashina has been or is currently a principal investigator of clinical trials funded by Alder BioPharmaceuticals, Amgen, electroCore, Novartis, and Teva. Dr. Messoud Ashina is as an associate editor of Cephalalgia, Headache, and the Journal of Headache and Pain. Dr. Messoud Ashina reports research grants from the Lundbeck Foundation, Novo Nordisk Foundation, and Research Foundation of the Capital Region of Denmark. Dr. Richard B. Lipton is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Multiple Principal Investigator), 5\u2009U10 NS077308 (Principal Investigator), RO1 NS082432 (Investigator), 1RF1 AG057531 (Site Principal Investigator), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), and 1K01AG054700 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics and Biohaven Holdings; and serves as consultant, advisory board member, or has received honoraria from the American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy\u2019s, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merc k, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff\u2019s Headache, 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. Dr. Henrik W. Schytz has received speaking fees from Novartis, Eli Lilly, and Teva. Dr. Henrik W. Schytz has received a research grant from Novartis. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}